Top-News
Ein Milliarden Dollar Unternehmen wurde geboren?
Beiträge: 138
Zugriffe: 19.180 / Heute: 11
Zugriffe: 19.180 / Heute: 11
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +59,87%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +52,57%
AMUNDI ETF MSCI EUROPE BANKS UCITS ETF
Perf. 12M: +36,70%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +34,41%
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
"Protein misfolding and aggregation plays a significant role in a wide range of human diseases, including very common diseases such as Parkinson's and Alzheimer's, as well as many rare and ultra-rare diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "MANF has a unique ability to mediate protein folding in an extracellular fashion, making it potentially an ideal biologic drug candidate for a wide range of human conditions. Parkinson's continues to remain the Company's primary focus, especially in light of recently announced data where MANF demonstrated superiority over GDNF in a neurorestoration animal model of Parkinson's disease. However, the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's utility in diseases that have much smaller patient populations, and we will make a concerted effort to focus on rare and ultra-rare diseases when reviewing the results. This strategy may afford the Company an accelerated pathway to commercialization by identifying therapeutic applications for MANF that would require few small clinical trials. Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."
The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.[1]
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
[1] www.fda.gov/ForIndustry/...rphanProductDesignation/default.htm
MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com
"Protein misfolding and aggregation plays a significant role in a wide range of human diseases, including very common diseases such as Parkinson's and Alzheimer's, as well as many rare and ultra-rare diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "MANF has a unique ability to mediate protein folding in an extracellular fashion, making it potentially an ideal biologic drug candidate for a wide range of human conditions. Parkinson's continues to remain the Company's primary focus, especially in light of recently announced data where MANF demonstrated superiority over GDNF in a neurorestoration animal model of Parkinson's disease. However, the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's utility in diseases that have much smaller patient populations, and we will make a concerted effort to focus on rare and ultra-rare diseases when reviewing the results. This strategy may afford the Company an accelerated pathway to commercialization by identifying therapeutic applications for MANF that would require few small clinical trials. Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."
The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.[1]
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
[1] www.fda.gov/ForIndustry/...rphanProductDesignation/default.htm
MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com
warum sollten die auf 1-3 Dollar gehen?
Why we are going Higher!
1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
Das is geil: "6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!"
Es gibt noch weitere Infos:
a) Is nicht so wichtig
b) Hab ich vergessen
c) Hat der Hund gefressen
d) WEIL HALT!
Es gibt noch weitere Infos:
a) Is nicht so wichtig
b) Hab ich vergessen
c) Hat der Hund gefressen
d) WEIL HALT!
Doppel-ID, Doppel-D, alles eine Baustelle!
hab mir mal Ihre Webseite angeschaut, und in USA Hammervolumen. Ich gönn mir mal welche.
Musst ja nicht rein, aber wäe früh genug rein ist, der hat jetzt schon mehrere 100 % Plus in seinem Depot stehen!
...selbst mit dem Anstieg der letzten Tage...
Doppel-ID, Doppel-D, alles eine Baustelle!
zum Jahresende. Da gibts im Januar ein zweites Weihnachten. Ich drück euch daumen ihr Himmelhunde!!
ist das interessante ist nach ein wenig in der letzten Zeit wahnsinnig gestiegen.
hier wird die Kohle gemacht. Jungs bleibt bei der Stange, es lohnt sich.
der Kurs wird weiter steigen. Wahnsinnspotential.
bin ja mal gespannt wies am Nachmittag weiter geht :-)
in den US Foren heiß empfohlen!
in den US Foren heiß empfohlen!
www.finanznachrichten.de/nachrichten-2012-11/25047300…
Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
von 0,06 - 0,07 Dollar!
Watch for the gap up today if history repeats itself this week might see anoher 200% climb!
Between the new board member having many connections and AMBS being in direct contact with people like the co founder of Amgen we are on the verge of great things to come. Then there is the Manhattan law firm we brought on board two weeks ago the message board has been quiet about this but this is big news as well. Because we got one of the best law firms in the country to help secure a deal for the further development of our main drug line. This must have been done after the positive test results came back from the lab. Now it's a wait and see approach but when the JV is announced the gap up that morning between the closing bid and the open bid will be a historical leap! That day might be this morning or it might not be until next month but one thing is for certain the day is approaching and good things will come to thous of us who hold a long position in this stock. Good Luck to us!!
Sentiment: Strong Buy
Sentiment: Strong Buy
da werden einige sich noch ganz schön die augen reiben, wenn usa eröffnet, dieses Kurs würde ich nie und nimmer bezahlen, vielleicht später
SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
NEWPORT BEACH, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- BUYINS.NET, www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through November 2, 2012. The total aggregate number of shares shorted since June 2011 is approximately 80.66 million shares. Approximately 24.65% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.02. A short squeeze has begun as AMBS is above its $0.02 SqueezeTrigger Price.
26% Plus - extreme Konsolidierungen - viele große Käufe bei 0,07-0,08 $ - Morgen sind dann die 0,10 $ möglich
Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
SUNNYVALE, Calif., Nov. 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today updated shareholders on the timing of the final data set from its grant from the Michael J. Fox Foundation being released to the marketplace. The Company expects to have the data set available in December. Upon completion of the data analysis correlate of the positive behavioural animal data for MANF previously reported with histology data confirming re-innervation of the striatum due to MANF delivery to the substantia nigra, the Michael J. Fox Foundation will consider funding additional studies to advance MANF as a disease-modifying treatment for Parkinson's disease.
aus dem amerikanischen ihub übernommen:
HERE IS THE EMAIL REPLY I RECIEVED FROM CEO. I was going to wait to load up in the morning before posting this but F it, ill chase. I think its unfair to share with some and let others be a victim of false scare tactics by shorts or bashers trying to get in lower. READ THIS AND BE AMAZED.
The email I sent is at the bottom.
Quote:Hello Haris,
THe Foundation believes that MANF is a promising candidate, as they stated at the end of the corrected PR. The correction was released because none of the data has been submitted to the Foundation yet for their scrutiny. The behavioral data is pretty clear in my opinion, and you can see the actual figures for yourself in the 8K submitted Friday October 28th, 2012 in Figure 2 (MANF 10ug vs GDNF) www.sec.gov/Archives/edgar/data/1424812/...2059055/v327259_ex99-1.htm .
However, as pointed out in John's quote from the data press release dated October 25th, 2012 finance.yahoo.com/news/...ces-manf-demonstrates-121100974.html the behavioral data is positive, but we do not yet have the histology data to confirm that reinnervation of the striatum has occurred. Until that data, expected in December, correlates by proving neurite outgrowth in the striatum, the Fox Foundation does not consider the result to be confirmed.
Hence, as we went through various drafts, we were supposed to leave any discussion otu altogether, but in fact I uploaded the original draft as opposed to the final draft, for the update release. This was a simple human error on my part, and had nothing to do with seeking to misrepresent reality with the Foundation.
The Fox Foundation is awaiting the full data set to evaluate the correlation of the histology to the behavior before they will pass judgment on the quality of the result. That is the correct position from the scientific standpoint, especially given the implication. If confirmed, MANF would be the first neurotrophic factor in history to do this, so caution is advised before passing judgment.
Despite the correlation question, MANF is already the first neurotrophic factor to correct behavior aspects of this animal model, and that is why we released the behavior absent the histology; because we felt it was such an important finding it was likely to positively impact shareholder value which had been suffering for so long.
I thank you for your involvement in Amarantus and your belief in what we are doing. We beleive in it strongly as well and we are hopeful that we will be able to further improve shareholder value for the long term. I am a large shareholder as well, and so my interests are 100% alligned with those who take a long term view of Amarantus.
Best Regards,
Gerald
On Sat, Nov 10, 2012 at 3:08 PM, Haris Xxxx wrote:
Hello Mr. Gerald,
I am a shareholder of Amarantus BioSciences and had a question. Im pretty sure you already have a few emails about this but I just want to make sure myself as I truly believe in this company and invested here for long term. I wanted to know what the correction PR was about. Is it MJFF changing their position about believing in MANF's success? Do they not believe in this drug anymore? A little clarification would be greatly appreciated.
Thanks.
Haris.
Wir reden hier über wirklich bahnbrechende Therapieformen zur Behandlung von Parkinson - und die Pregnosen sind excellent. Hier tut sich gerade ein Miolliarden-Dollar-Markt für eine Firma auf, die gerade mal mit ein paar lächerlichen Millionen bewertet ist.
Nur meine bescheidene Meinung, aber wenn die Ergebnisse im Dezember gut ausfallen, dann reden wir hier ohne weiteres von einem Aktienkurs von jenseits 1 $ !
HERE IS THE EMAIL REPLY I RECIEVED FROM CEO. I was going to wait to load up in the morning before posting this but F it, ill chase. I think its unfair to share with some and let others be a victim of false scare tactics by shorts or bashers trying to get in lower. READ THIS AND BE AMAZED.
The email I sent is at the bottom.
Quote:Hello Haris,
THe Foundation believes that MANF is a promising candidate, as they stated at the end of the corrected PR. The correction was released because none of the data has been submitted to the Foundation yet for their scrutiny. The behavioral data is pretty clear in my opinion, and you can see the actual figures for yourself in the 8K submitted Friday October 28th, 2012 in Figure 2 (MANF 10ug vs GDNF) www.sec.gov/Archives/edgar/data/1424812/...2059055/v327259_ex99-1.htm .
However, as pointed out in John's quote from the data press release dated October 25th, 2012 finance.yahoo.com/news/...ces-manf-demonstrates-121100974.html the behavioral data is positive, but we do not yet have the histology data to confirm that reinnervation of the striatum has occurred. Until that data, expected in December, correlates by proving neurite outgrowth in the striatum, the Fox Foundation does not consider the result to be confirmed.
Hence, as we went through various drafts, we were supposed to leave any discussion otu altogether, but in fact I uploaded the original draft as opposed to the final draft, for the update release. This was a simple human error on my part, and had nothing to do with seeking to misrepresent reality with the Foundation.
The Fox Foundation is awaiting the full data set to evaluate the correlation of the histology to the behavior before they will pass judgment on the quality of the result. That is the correct position from the scientific standpoint, especially given the implication. If confirmed, MANF would be the first neurotrophic factor in history to do this, so caution is advised before passing judgment.
Despite the correlation question, MANF is already the first neurotrophic factor to correct behavior aspects of this animal model, and that is why we released the behavior absent the histology; because we felt it was such an important finding it was likely to positively impact shareholder value which had been suffering for so long.
I thank you for your involvement in Amarantus and your belief in what we are doing. We beleive in it strongly as well and we are hopeful that we will be able to further improve shareholder value for the long term. I am a large shareholder as well, and so my interests are 100% alligned with those who take a long term view of Amarantus.
Best Regards,
Gerald
On Sat, Nov 10, 2012 at 3:08 PM, Haris Xxxx wrote:
Hello Mr. Gerald,
I am a shareholder of Amarantus BioSciences and had a question. Im pretty sure you already have a few emails about this but I just want to make sure myself as I truly believe in this company and invested here for long term. I wanted to know what the correction PR was about. Is it MJFF changing their position about believing in MANF's success? Do they not believe in this drug anymore? A little clarification would be greatly appreciated.
Thanks.
Haris.
Wir reden hier über wirklich bahnbrechende Therapieformen zur Behandlung von Parkinson - und die Pregnosen sind excellent. Hier tut sich gerade ein Miolliarden-Dollar-Markt für eine Firma auf, die gerade mal mit ein paar lächerlichen Millionen bewertet ist.
Nur meine bescheidene Meinung, aber wenn die Ergebnisse im Dezember gut ausfallen, dann reden wir hier ohne weiteres von einem Aktienkurs von jenseits 1 $ !
und die Umsätze der vergangenen Woche - der Chart ist absolut bullish und ich würde mich überhaupt nicht wundern, wenn wir in dieser WOche locker über 0,10 $ landen.
Noch ist Zeit, günstig einzusteigen...und die ersten Umsätze in D zeigen das ja auch schon an, obwohl die Musik eindeutig in den USA gemacht wird !
Noch ist Zeit, günstig einzusteigen...und die ersten Umsätze in D zeigen das ja auch schon an, obwohl die Musik eindeutig in den USA gemacht wird !
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.
The fundamental scientific premise of reducing protein misfolding is basic, yet very profound.
The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury.
These are all indications with very large markets and clear unmet medical need.
I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously.
MANF has the commercial potential to become a blockbuster drug."
www.marketwatch.com/story/...feld-to-advisory-board-2012-11-06
Wenn das jemand mit der Erfahrung und der Reputation eines Dr. Rubinfeld in dieser wirklich begeisternden Art und Weise berichtet, dann haben wir hier einen absoluten Rohdiamanten am Start, der uns noch ganz viel Freude machen wird.
Mal ganz abgesehen davon, dass jetzt mal bloß ein großer Konzern kommen muss und die Firma gerne kaufen möchte...was sind da schon 100 oder 200 Millionen bei DEN Aussichten.
Aber bei aller Euphorie - alles nur meine bescheidene Meinung und um Himmels Willen keine Kaufempfehlung.
aus dem amerikanischen Board:
REASONS WE ARE GOING HIGHER: Great info by akmersil
1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:14 PM.Permalink
.
1. AMBS acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC
2. AMBS had Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
3. AMBS Secured the license for the NuroPro Parkinson's diagnostic blood test;
4. AMBS Successfully concluded its research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
5. AMBS anticipates announcing interim results from on-going delivery experiments by the end of October.
6. AMBS has a Parkinson’s disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinson’s—a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s research...
7. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinson’s that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients. The Companies believe that Amarantus’ NuroPro test for Parkinson’s disease could be on market in certain regions as early as 2013.
8. Over $30MM has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.
9. According to a2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75BB by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson’s drug market. There are currently no diagnostic tests available for Parkinson’s disease, thus making AMBS test a first of its kind product capable of gaining a market leading position.
10. AMBS announced Drug Test Results & the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls
.
5users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:20 PM.Permalink
.
With cases of Parkinson’s disease sharply on the rise as the world’s population ages, the costs associated with the illness are rapidly rising, too. Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC) is working on new solutions to help reduce the global costs associated with Parkinson’s and other neurological diseases.
Experts estimate that up to 10 million people worldwide are currently living with Parkinson’s, including as many as one million Americans. An average of 60,000 Americans are diagnosed with the disease each year, but that number doesn’t include thousands of cases that go undetected or undiagnosed.
What’s worse, the numbers are growing.
There is reason for hope, however. RBCC is currently negotiating a definitive agreement with Amarantus Biosciences (AMBS), a company that could be on the verge of revolutionary new diagnostic and therapeutic tools for Parkinson’s patients and their doctors.
RBCC is working to deliver breakthroughs like these to the people who need them most. The market for Parkinson’s drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain.
Sentiment: Strong Buy
.
3users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..View Replies.
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 10:06 PM.Permalink
.
Form 8-K for AMARANTUS BIOSCIENCES, INC.
--------------------------------------------------
31-Oct-2012
Other Events
Item 8.01. Other Events
On October 26, 2012, Amarantus BioSciences, Inc. issued a Convertible Promissory Note to Dr. Joseph Rubinfeld, co-founder of Amgen, in the principal amount of $10,000.00 The Note bears interest at the rate of six percent (6%) per annum until paid in full and is convertible into shares of Amarantus common stock at the price of $0.01 per share upon ten (10) days written notice to Amarantus. Dr. Joseph Rubinfeld has submitted a conversion notice to convert his entire note into common stock, for a total 1,000,000 common shares, to be issued within 10 days.
The principal amount of the Note is not material to Amarantus and if converted, the number of shares issued in conversion would be less that one percent (1%) of the outstanding shares of Amarantus
.
1users liked this posts0users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 4, 2012 12:13 PM.Permalink
.
Sept. 24, 2012 –/PRNewswire/ — Amarantus BioSciences, Inc.
“Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson`s was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials.” The report also states: “Amarantus owns the license for Power3 Medical Products` NuroPro Blood Test as it relates to Parkinson`s disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies
Sentiment: Strong Buy
REASONS WE ARE GOING HIGHER: Great info by akmersil
1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:14 PM.Permalink
.
1. AMBS acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC
2. AMBS had Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
3. AMBS Secured the license for the NuroPro Parkinson's diagnostic blood test;
4. AMBS Successfully concluded its research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
5. AMBS anticipates announcing interim results from on-going delivery experiments by the end of October.
6. AMBS has a Parkinson’s disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinson’s—a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s research...
7. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinson’s that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients. The Companies believe that Amarantus’ NuroPro test for Parkinson’s disease could be on market in certain regions as early as 2013.
8. Over $30MM has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.
9. According to a2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75BB by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson’s drug market. There are currently no diagnostic tests available for Parkinson’s disease, thus making AMBS test a first of its kind product capable of gaining a market leading position.
10. AMBS announced Drug Test Results & the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls
.
5users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:20 PM.Permalink
.
With cases of Parkinson’s disease sharply on the rise as the world’s population ages, the costs associated with the illness are rapidly rising, too. Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC) is working on new solutions to help reduce the global costs associated with Parkinson’s and other neurological diseases.
Experts estimate that up to 10 million people worldwide are currently living with Parkinson’s, including as many as one million Americans. An average of 60,000 Americans are diagnosed with the disease each year, but that number doesn’t include thousands of cases that go undetected or undiagnosed.
What’s worse, the numbers are growing.
There is reason for hope, however. RBCC is currently negotiating a definitive agreement with Amarantus Biosciences (AMBS), a company that could be on the verge of revolutionary new diagnostic and therapeutic tools for Parkinson’s patients and their doctors.
RBCC is working to deliver breakthroughs like these to the people who need them most. The market for Parkinson’s drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain.
Sentiment: Strong Buy
.
3users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..View Replies.
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 10:06 PM.Permalink
.
Form 8-K for AMARANTUS BIOSCIENCES, INC.
--------------------------------------------------
31-Oct-2012
Other Events
Item 8.01. Other Events
On October 26, 2012, Amarantus BioSciences, Inc. issued a Convertible Promissory Note to Dr. Joseph Rubinfeld, co-founder of Amgen, in the principal amount of $10,000.00 The Note bears interest at the rate of six percent (6%) per annum until paid in full and is convertible into shares of Amarantus common stock at the price of $0.01 per share upon ten (10) days written notice to Amarantus. Dr. Joseph Rubinfeld has submitted a conversion notice to convert his entire note into common stock, for a total 1,000,000 common shares, to be issued within 10 days.
The principal amount of the Note is not material to Amarantus and if converted, the number of shares issued in conversion would be less that one percent (1%) of the outstanding shares of Amarantus
.
1users liked this posts0users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 4, 2012 12:13 PM.Permalink
.
Sept. 24, 2012 –/PRNewswire/ — Amarantus BioSciences, Inc.
“Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson`s was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials.” The report also states: “Amarantus owns the license for Power3 Medical Products` NuroPro Blood Test as it relates to Parkinson`s disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies
Sentiment: Strong Buy
Die wichtigsten Absätze in den News, finde ich:
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
"Dr. Zimmerman's extensive experience in drug development and his focus on risk mitigation will be extremely helpful as we begin to position MANF as a potential game-changing technology across a broad spectrum of applications related to apoptosis. While Parkinson's remains our lead application, a comprehensive approach to advancing MANF towards the clinic may help us identify other opportunities that could substantially improve shareholder value in the near-term, without the deployment of significant additional resources," added Gerald E. Commissiong, President and CEO of Amarantus.
WOW...da haben sie sich ja einen weiteren richtig guten Mann ins Boot geholt !
UND es geht hier nicht nur um die Behandlung von Parkinson, sondern um eine Vielzahl von Anwendungsmöglichkeiten, die den shareholder value near-term vergrößern können. Da kann man dann wirklich nur noch sagen: WOW !!!
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
"Dr. Zimmerman's extensive experience in drug development and his focus on risk mitigation will be extremely helpful as we begin to position MANF as a potential game-changing technology across a broad spectrum of applications related to apoptosis. While Parkinson's remains our lead application, a comprehensive approach to advancing MANF towards the clinic may help us identify other opportunities that could substantially improve shareholder value in the near-term, without the deployment of significant additional resources," added Gerald E. Commissiong, President and CEO of Amarantus.
WOW...da haben sie sich ja einen weiteren richtig guten Mann ins Boot geholt !
UND es geht hier nicht nur um die Behandlung von Parkinson, sondern um eine Vielzahl von Anwendungsmöglichkeiten, die den shareholder value near-term vergrößern können. Da kann man dann wirklich nur noch sagen: WOW !!!
ich wollte gerade in berlin ordern. Gattung gesperrt??? hatte jemand schon sowas? ich habe genug geld auf dem Konto, was kann der Grund für so eine Meldung sein?
dank für infos.
dank für infos.
was da seit Wochen los ist...das Ding brennt noch richtig denke.
absolut marginal und für den Kursverlauf in den USA vollkommen belanglos...aber vielleicht ändert sich das in den kommenden Tagen ja noch, wenn hier mehr und mehr Trader ein bißchen Zeit investieren, um sich über die fantastischen Aussichten von Amarantus zu informieren.
Da kommt bis Jahresende was richtig Großes auf uns zu...und auch wenn der gestrige Tag für diejenigen, die bei knaßß 7 ct eingestiegen sind, scheiße ausgesehen hat, dürften das in einem Monat Schnäppchenpreise gewesen sein.
Hallo - wir reden hier über einen Milliarden-Dollar-Markt...und die Firma ist gerade jetzt dabei, sich für diesen Markt perfekt zu positionieren.
Ihr Team stellen sie ja gerade zusammen...und was für ein gutes !!!
Alles nur meine Meinung - die Entscheidung trefft ihr ganz alleine
Da kommt bis Jahresende was richtig Großes auf uns zu...und auch wenn der gestrige Tag für diejenigen, die bei knaßß 7 ct eingestiegen sind, scheiße ausgesehen hat, dürften das in einem Monat Schnäppchenpreise gewesen sein.
Hallo - wir reden hier über einen Milliarden-Dollar-Markt...und die Firma ist gerade jetzt dabei, sich für diesen Markt perfekt zu positionieren.
Ihr Team stellen sie ja gerade zusammen...und was für ein gutes !!!
Alles nur meine Meinung - die Entscheidung trefft ihr ganz alleine
www.amarantus.com/investor-relations/videos.html
barchart.com/quotes/stocks/AMBS
americanbulls.com/...icker=AMBS&MarketTicker=OTC&TYP=S
americanbulls.com/...icker=AMBS&MarketTicker=OTC&TYP=S
zieht euch mal schön warm an...oder besser: zieht euch mal ganz schnell aus, denn das hier wird richtig, richtig heiß werden...und da wollen wir doch mal schauen, wie das mit dem covern so weitergeht heute *grins, freu*
ich werd mal 2000 $ heute Nachmittag investieren !
Danke für die Info....könnte in den nächsten Wochen ein kleines Extra - Weihnachtsgeld geben....
:-))
Danke für die Info....könnte in den nächsten Wochen ein kleines Extra - Weihnachtsgeld geben....
:-))
Im Moment kommt man - besonders gleich zu Handelsbeginn - noch ganz günstig rein.
Aber macht euch mal klar, was passiert, wenn Anfang Dezember die MANF-Ergebnisse vorliegen...wow, da darf man dann mal über ein richtig geiles Weihnachtsgeld nachdenken.
Und alleine der Therapie-Markt für Parkinson ist milliardenschwer.
Und die Anwendungsgebiete für MANF noch viel, viel größer.
Hallo, da werden aber jetzt schon die Jungs von Pfizer und andere mal ganz genau hinschauen, ob sie sich diese Firma mal einverleiben sollten.
Die werden sich aber bestimmt nicht unter Wert verkaufen.
Aber macht euch mal klar, was passiert, wenn Anfang Dezember die MANF-Ergebnisse vorliegen...wow, da darf man dann mal über ein richtig geiles Weihnachtsgeld nachdenken.
Und alleine der Therapie-Markt für Parkinson ist milliardenschwer.
Und die Anwendungsgebiete für MANF noch viel, viel größer.
Hallo, da werden aber jetzt schon die Jungs von Pfizer und andere mal ganz genau hinschauen, ob sie sich diese Firma mal einverleiben sollten.
Die werden sich aber bestimmt nicht unter Wert verkaufen.
ih.advfn.com/p.php?pid=nmona&article=54876125
Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board Print Alert Amarantus Biosci (OTCBB:AMBS)
SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board.
Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.
The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need.
I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously.
MANF has the commercial potential to become a blockbuster drug."
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
"Clearly, Dr. Rubinfeld joining the Advisory Board is a tremendous endorsement for the Company at this critical juncture in our growth cycle," said Gerald E. Commissiong, President & CEO of Amarantus. "The Advisory Board is now well populated with extremely talented experts in the various fields that are necessary to position us for growth: science, investment banking/M&A, business development and regulatory affairs. We now intend to leverage these relationships to fill out the management team and Board of Directors with development expertise and Big Pharma experience in order to attract the capital necessary to advance our development programs towards key value inflexion milestones."
Wenn jemand von der Reputation eines Dr. Rubinfeld so euphorisch davon spricht, dass das hier einer der größten Erfolge werden könnte, die er jemals gesehen hat, dann überzeugt mich das wirklich !
eigentlich schon Neuigkeiten wie es weitergeht, nachdem der Artikel ja dementiert wurde?
die Testergebnisse für MANF in Bezug auf Parkinson geben soll...und dann kommt ja möglicherweise (oder sehr sicher, je nach Betrachtungsweise) die MJFF wieder ins Spiel mit einer entsprechenen Unterstützung.
Das sollte spätestens der Treibsatz für diese Rakete hier sein...positive Resultate vorausgesetzt, na klar, sonst funktioniert sowas natürlich nicht :-)
Ich bin auf jeden Fall mal sehr gespannt, wie lange die Shorties und andere Manipulierer den Kurs noch auf diesem niederigen Niveau halten können.
Ach - und die nachbörsliche Meldung über einen neuen Investor, der mal eben so 500.000 $ zu einem Kurs von 0,051 $ investiert, sollte hier durchaus als deutliches Signal in das Vertrauen zu Amarantus gewertet werden. 500.000 $ investiere ich nicht in eine Luftnummer a la TAGG, wo der einzige Treibsatz in einer möglichen Übernahmephantasie besteht. Ein Investor in der Größenordnung wird sich schon sehr eingehend mit Amarantus und die Möglichkeiten, die sich hier auftun, beschäftigt haben.
Das sollte spätestens der Treibsatz für diese Rakete hier sein...positive Resultate vorausgesetzt, na klar, sonst funktioniert sowas natürlich nicht :-)
Ich bin auf jeden Fall mal sehr gespannt, wie lange die Shorties und andere Manipulierer den Kurs noch auf diesem niederigen Niveau halten können.
Ach - und die nachbörsliche Meldung über einen neuen Investor, der mal eben so 500.000 $ zu einem Kurs von 0,051 $ investiert, sollte hier durchaus als deutliches Signal in das Vertrauen zu Amarantus gewertet werden. 500.000 $ investiere ich nicht in eine Luftnummer a la TAGG, wo der einzige Treibsatz in einer möglichen Übernahmephantasie besteht. Ein Investor in der Größenordnung wird sich schon sehr eingehend mit Amarantus und die Möglichkeiten, die sich hier auftun, beschäftigt haben.
aber was sagst Du zu diesem Artikel?
Nicht gerade sehr förderlich, m.M.n.
www.hotstocked.com/article/40622/...c-otc-ambs-wobbles-as.html
Nicht gerade sehr förderlich, m.M.n.
www.hotstocked.com/article/40622/...c-otc-ambs-wobbles-as.html
Sehe ich mit Blick auf die Fundamentals und die verzweifelten Versuche der Shorties, den Kurs zu drücken vollkommen anders.
Aber wer hier der Meinung ist, wir sind jetzt bereits überkauft und das wars hier schon mit dem Run, sollte hier wirklich die Finger davon lassen.
Das schöne an Amarantus ist, dass wir hier in D nur ein winziger Nebenkriegsschauplatz sind, aber in den USA investieren und an dem Run teilhaben dürfen.
Wenn eine TAGG mit heißer Luft und gasnz viel Pennypush-Blättchen auf über 40 US-Cent rauschen kann, dann sind hier aber ganz andere Kursziele angesagt.
Und dass sowas ganz schnell gehen kann, zeigen die Amis immer wieder ;-))
Aber wer hier der Meinung ist, wir sind jetzt bereits überkauft und das wars hier schon mit dem Run, sollte hier wirklich die Finger davon lassen.
Das schöne an Amarantus ist, dass wir hier in D nur ein winziger Nebenkriegsschauplatz sind, aber in den USA investieren und an dem Run teilhaben dürfen.
Wenn eine TAGG mit heißer Luft und gasnz viel Pennypush-Blättchen auf über 40 US-Cent rauschen kann, dann sind hier aber ganz andere Kursziele angesagt.
Und dass sowas ganz schnell gehen kann, zeigen die Amis immer wieder ;-))
Not really worried about regular shorts!!
FTD's are more important here! The longer they are out the harder it is for MM's to deliver naked shares if in a large amount!!
Just like VKN* the FTD's did that stock in back in Oct 2009!!
Time was running out and a few BIG MM's were severely short and would not be able to trade in stock!!
And as time came on an good NEWS happened the stock VIOLANTLY rocketed up!
From $0.0031 to $1.10!!
This is VERY SIMILAR the lowest point in AMBS was $0.0048!!
FTD's are more important here! The longer they are out the harder it is for MM's to deliver naked shares if in a large amount!!
Just like VKN* the FTD's did that stock in back in Oct 2009!!
Time was running out and a few BIG MM's were severely short and would not be able to trade in stock!!
And as time came on an good NEWS happened the stock VIOLANTLY rocketed up!
From $0.0031 to $1.10!!
This is VERY SIMILAR the lowest point in AMBS was $0.0048!!
zum Glück hatte ich gewartet....
bei 0,004 steige ich wieder ein
bei 0,004 steige ich wieder ein
Wahrscheinlich wurde das 8k falsch interpretiert und nun stellt sich wohl raus, das 6 Monate keine neue Aktien kommen! Ein grosser Investor hat 0,10 Dollarcent pro Aktie bezahlt und da sollte der Kurs demnächst auch stehen!
Weiss einer schon mehr,ob es nur falsch interpretiert wurde?und
würde das dann bedeuten das diese 1 Milliarden Aktien erst in 6 Monaten kommen.
Der Kurs hatte sich ja zum Schluss wieder einwenig gefangen.
würde das dann bedeuten das diese 1 Milliarden Aktien erst in 6 Monaten kommen.
Der Kurs hatte sich ja zum Schluss wieder einwenig gefangen.
AMBS-Amarantus BioSciences Secures $1.1 Million in Financing
MAJOR NEWS RELEASED NEAR END OF BELL!
Wed Nov 14, 1:53PM CST
SUNNYVALE, Calif. , Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.
"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong , President and CEO of Amarantus. "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."
Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000 . The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.
Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.
MAJOR NEWS RELEASED NEAR END OF BELL!
Wed Nov 14, 1:53PM CST
SUNNYVALE, Calif. , Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.
"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong , President and CEO of Amarantus. "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."
Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000 . The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.
Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.
rauscht heute noch weiter runder.....schaut mal wo die aktie herkam
Ich glaube nicht das es noch weiter runter geht, sonst hätte der investor doch nicht für das stk 0,10 bezahlt.
Warten wir mal ab was da noch kommt die nächten tage.
Warten wir mal ab was da noch kommt die nächten tage.
das sind ja 0,10$ nicht Euro, in euro sind das derzeit 0,07€
ich bin sher gespannt, wie es weitergeht...
ich bin sher gespannt, wie es weitergeht...
Amarantus BioSciences Secures $1.1 Million in Financing
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Amarantus BioSciences, Inc.
Convertible Note investment into the Company priced at $0.10 per share
SUNNYVALE, Calif., Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.
"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong, President and CEO of Amarantus. "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."
Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000. The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.
Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.
Amarantus BioSciences, Inc.
(408) 737-2734
pr@amarantus.com
Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Amarantus BioSciences, Inc.
Convertible Note investment into the Company priced at $0.10 per share
SUNNYVALE, Calif., Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.
"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong, President and CEO of Amarantus. "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."
Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000. The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.
Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.
Amarantus BioSciences, Inc.
(408) 737-2734
pr@amarantus.com
Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com
in berlin weitergehandelt oder gibt es wie in frankfurt auch delistings zum 15.12.?
wenn ja, ist amarantus betroffen?
wenn ja, ist amarantus betroffen?
was denn nun, erst schreibst du "rauscht heute runter" (09:58 / #77) und jetzt auf einmal "könnte heute explodieren"? Du musst dich schon mal festlegen, sonst wird´s ein bischen unglaubwürdig! ;-)
Bei 0,006 einzusteigen, versuche es halt mal bei 0,06:-)
wenn ich se für weniger bekommen werde....
warten wirs ab...hihi
warten wirs ab...hihi
hier passiert auch nix mehr, ausser das der Kurs runter geht!
www.finanznachrichten.de/...ceo-letter-to-shareholders-008.htm
NOKOMIS, Fla., Nov 19, 2012 (BUSINESS WIRE) -- As Rainbow Coral Corp. looks ahead to a successful 2013, the company has placed a high priority on initiating projects that will realize profits quickly.
The first project to be fast-tracked will be the company's joint venture with Amarantus BioSciences (OTCBB: AMBS). Both companies forswear realizing revenues from the impending commercialization of Amarantus' NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson's disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.
RBCC and Amarantus expect to finalize NuroPro's development timeline within the next 12-14 months. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal.
The shortened timeline became a possibility last week when Amarantus secured over $1.1 million in funding through two separate transactions. RBCC plans to invest in the ongoing development of NuroPro and to be repaid for its investment out of proceeds from the sales generated by the revolutionary diagnostic blood test.
If milestones are met, RBCC will then share in its revenues sooner than originally anticipated, once the initial investment is repaid.
For more information on Rainbow BioSciences' neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
SOURCE: Rainbow BioSciences, LLC
CONTACT:
Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO info@rainbowcoral.com
Copyright Business Wire 2012
The first project to be fast-tracked will be the company's joint venture with Amarantus BioSciences (OTCBB: AMBS). Both companies forswear realizing revenues from the impending commercialization of Amarantus' NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson's disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.
RBCC and Amarantus expect to finalize NuroPro's development timeline within the next 12-14 months. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal.
The shortened timeline became a possibility last week when Amarantus secured over $1.1 million in funding through two separate transactions. RBCC plans to invest in the ongoing development of NuroPro and to be repaid for its investment out of proceeds from the sales generated by the revolutionary diagnostic blood test.
If milestones are met, RBCC will then share in its revenues sooner than originally anticipated, once the initial investment is repaid.
For more information on Rainbow BioSciences' neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
SOURCE: Rainbow BioSciences, LLC
CONTACT:
Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO info@rainbowcoral.com
Copyright Business Wire 2012
www.finanznachrichten.de/...patent-challenge-in-europe-008.htm
Patentschlacht geht es jetzt aber runter... ;-(
Was meint ihr, wo geht es noch hin?
Was meint ihr, wo geht es noch hin?
der Thread sollte eher "ein Milliardengrab" heissen ;-)
RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit
NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) nears a new joint venture agreement to commercialize advances made by Amarantus BioSciences (OTCBB: AMBS), the company’s latest target continues to seek out additional investment capital from high-profile investors.
“We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike”
Amarantus Chief Science Officer John W. Commissiong recently presented his organization’s brilliant MANF therapeutic protein for Parkinson’s disease at the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings together researchers, developers and investors to collaborate in bringing new treatments to patients suffering from brain disorders.
The high-profile event put Amarantus’ proprietary, anti-apoptosis therapeutic protein in the spotlight in front of researchers and investors from around the world.
“We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike,” said RBCC CEO Patrick Brown. “We look forward to wrapping up our joint venture agreement shortly, and then our first priority will be moving their groundbreaking therapeutics forward toward full commercialization.”
Both companies forswear realizing revenues from the impending commercialization of Amarantus’ NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson’s disease. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal. Next in line for commercialization will be MANF.
For more information on Rainbow BioSciences’ neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contacts
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) nears a new joint venture agreement to commercialize advances made by Amarantus BioSciences (OTCBB: AMBS), the company’s latest target continues to seek out additional investment capital from high-profile investors.
“We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike”
Amarantus Chief Science Officer John W. Commissiong recently presented his organization’s brilliant MANF therapeutic protein for Parkinson’s disease at the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings together researchers, developers and investors to collaborate in bringing new treatments to patients suffering from brain disorders.
The high-profile event put Amarantus’ proprietary, anti-apoptosis therapeutic protein in the spotlight in front of researchers and investors from around the world.
“We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike,” said RBCC CEO Patrick Brown. “We look forward to wrapping up our joint venture agreement shortly, and then our first priority will be moving their groundbreaking therapeutics forward toward full commercialization.”
Both companies forswear realizing revenues from the impending commercialization of Amarantus’ NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson’s disease. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal. Next in line for commercialization will be MANF.
For more information on Rainbow BioSciences’ neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contacts
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
AMBS mentioned in Seeking Alpha Article (big boards)!!
Seems like the news says the company hasn't sold any shares since the 10Q got released. I've been waiting quiet to get in again today.
Been playing ACAD (big board) and saw a seeking alpha article mentioning AMBS. Don't see seeking alpha posting stuff abt penny stocks that much but when it does, it does generate buzzzzZZZ
seekingalpha.com/article/...-focus-to-parkinson-s?source=yahoo
About AMBS:
Quote:
Amarantus Bioscience (AMBS.OB)is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
Quote:
The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, the company announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug.
About Parkinson's disease:
Quote:
Parkinson's disease psychosis is a debilitating disorder that develops in up to 60% of patients with Parkinson's disease. Currently, there is no FDA-approved therapy to treat PDP in the United States.
Seems like the news says the company hasn't sold any shares since the 10Q got released. I've been waiting quiet to get in again today.
Been playing ACAD (big board) and saw a seeking alpha article mentioning AMBS. Don't see seeking alpha posting stuff abt penny stocks that much but when it does, it does generate buzzzzZZZ
seekingalpha.com/article/...-focus-to-parkinson-s?source=yahoo
About AMBS:
Quote:
Amarantus Bioscience (AMBS.OB)is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
Quote:
The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, the company announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug.
About Parkinson's disease:
Quote:
Parkinson's disease psychosis is a debilitating disorder that develops in up to 60% of patients with Parkinson's disease. Currently, there is no FDA-approved therapy to treat PDP in the United States.
LEUTE WICHTIGE NACHRICHT IST RAUS!
KEINE DILUTION!
SEIT DER Q10 DIE AKTIENANZAHL NICHT GEÄNDERT!
WEDER MANAGEMENT NOCH OFFICERS HABEN AKTIEN VERKAUFT!
KEINER HAT AKTIEN VERÄUSSERT!
SOMIT SIND ALLE DIE DILUTION, PUMP & DUMP, VERAR**SCHE GESCHRIEN HABEN EIN FÜR ALLE MAL STUMM!
"The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals."
SUNNYVALE, Calif., Dec. 3, 2012
ih.advfn.com/p.php?pid=nmona&article=55291531
--------------------------------------------------
SOGAR ICH HABE DER FIRMA DERART ÜBLES LEISE UNTERSTELLT; DASS SIE EINEN HYPE LOSGELÖST HABEN UND AKTIEN VERHÖCKERN!
NACH WIE VOR SIE HABEN IM SINNE DER AKTIONÄRE GEHANDELT UND CONVERTIBLES FÜR 0,10 0,11 0,16 bis 0,20 VERGEBEN!
gute nacht leute, das sind sehr gute neuigkeiten! sollte den letzten zweifel wegräumen, und brauchen nicht den chart starren! der enge kreis hier weiss jetzt eigentlich ganz genau wo wir in paar monaten stehen werden. lasst euch von dummschwätzern auch nichts einreden,
auch im usbord standen ja die "longs" auch wie trottel da,die longs wären opfer von pump & dump, der ceo würde uns abzocken die firma würde dilutieren usw...jemand der kein mitgefühl und taktgefühl hat der hat nur ein axelzucken verdient, dieser knappe statement zeigt wo die firma steht und es nicht nötig hat mit fiesen tricks de aktionäre abzuzocken.
gute nacht bambi jotte herr lüdenscheidt timm hugedubel sundancer filbiremus thyr und alle anderen, haltet besser eure aktien fest, nichts ist verloren, und Larry bei Dir heisst es genau beobachten. vielleicht wie gesagt waren die 0,02 (für mich) und 0,018 für paar für euch weinachtsgeschenke der besonderen art.und danke an die basher! ;)
KEINE DILUTION!
SEIT DER Q10 DIE AKTIENANZAHL NICHT GEÄNDERT!
WEDER MANAGEMENT NOCH OFFICERS HABEN AKTIEN VERKAUFT!
KEINER HAT AKTIEN VERÄUSSERT!
SOMIT SIND ALLE DIE DILUTION, PUMP & DUMP, VERAR**SCHE GESCHRIEN HABEN EIN FÜR ALLE MAL STUMM!
"The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals."
SUNNYVALE, Calif., Dec. 3, 2012
ih.advfn.com/p.php?pid=nmona&article=55291531
--------------------------------------------------
SOGAR ICH HABE DER FIRMA DERART ÜBLES LEISE UNTERSTELLT; DASS SIE EINEN HYPE LOSGELÖST HABEN UND AKTIEN VERHÖCKERN!
NACH WIE VOR SIE HABEN IM SINNE DER AKTIONÄRE GEHANDELT UND CONVERTIBLES FÜR 0,10 0,11 0,16 bis 0,20 VERGEBEN!
gute nacht leute, das sind sehr gute neuigkeiten! sollte den letzten zweifel wegräumen, und brauchen nicht den chart starren! der enge kreis hier weiss jetzt eigentlich ganz genau wo wir in paar monaten stehen werden. lasst euch von dummschwätzern auch nichts einreden,
auch im usbord standen ja die "longs" auch wie trottel da,die longs wären opfer von pump & dump, der ceo würde uns abzocken die firma würde dilutieren usw...jemand der kein mitgefühl und taktgefühl hat der hat nur ein axelzucken verdient, dieser knappe statement zeigt wo die firma steht und es nicht nötig hat mit fiesen tricks de aktionäre abzuzocken.
gute nacht bambi jotte herr lüdenscheidt timm hugedubel sundancer filbiremus thyr und alle anderen, haltet besser eure aktien fest, nichts ist verloren, und Larry bei Dir heisst es genau beobachten. vielleicht wie gesagt waren die 0,02 (für mich) und 0,018 für paar für euch weinachtsgeschenke der besonderen art.und danke an die basher! ;)
auch noch aufgestockt!
Der Handel mit AMBS ist in Berlin beendet worden.
Nur die ISIN-Nummer geändert, gültig ab: 13. Dezember. 2012
Seite 1
Publication_038570.doc
Bekanntmachung
VERÄNDERUNGEN / CHANGES
Mit wirkung vom / gültig ab: 13. Dezember 2012
Name:
Amarantus BIOSCIE.
WKN:
A1JJ8L
ISIN:
US02300Q1058
Veränderung /
Ändern:
ISIN-Tausch
neue ISIN:
US02300T1097
neue WKN:
A1J9ZB
Name:
Prodigy Gold Inc
WKN:
A1H5YZ
ISIN:
CA74283A1003
Veränderung /
Ändern:
Fusion in Würfel Argonaut Gold Inc. im Verhältnis: 1 ST: 0,1042 ST in Aktien
der Argonaut Gold Inc. zzgl., Betrag:. CD 0,0001 WKN nach Tausch:, ISIN
nach Tausch:
neuer Bezeichnung
Argonaut Gold Inc
neue ISIN:
CA04016A1012
neue WKN:
A1C70D
Markieren
: Freiverkehr - variabel
Skontroführer
: 1172 mwb fairtrade Wertpapierhandelsbank AG
Berlin, den 12. Dezember 2012
Geschäftsführung DER BÖRSE BERLIN
Nur die ISIN-Nummer geändert, gültig ab: 13. Dezember. 2012
Seite 1
Publication_038570.doc
Bekanntmachung
VERÄNDERUNGEN / CHANGES
Mit wirkung vom / gültig ab: 13. Dezember 2012
Name:
Amarantus BIOSCIE.
WKN:
A1JJ8L
ISIN:
US02300Q1058
Veränderung /
Ändern:
ISIN-Tausch
neue ISIN:
US02300T1097
neue WKN:
A1J9ZB
Name:
Prodigy Gold Inc
WKN:
A1H5YZ
ISIN:
CA74283A1003
Veränderung /
Ändern:
Fusion in Würfel Argonaut Gold Inc. im Verhältnis: 1 ST: 0,1042 ST in Aktien
der Argonaut Gold Inc. zzgl., Betrag:. CD 0,0001 WKN nach Tausch:, ISIN
nach Tausch:
neuer Bezeichnung
Argonaut Gold Inc
neue ISIN:
CA04016A1012
neue WKN:
A1C70D
Markieren
: Freiverkehr - variabel
Skontroführer
: 1172 mwb fairtrade Wertpapierhandelsbank AG
Berlin, den 12. Dezember 2012
Geschäftsführung DER BÖRSE BERLIN
Kann weder in Berlin noch USA Order aufgeben was soll das Order wurde abgewiesen scheiß Postbank
wieder handeln, da ISIN Nummer gerade geändert wird!
Ok danke warte ich mal ab aber warum geht USA nicht
Interessanter Artikel:
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test
ih.advfn.com/...pid=nmona&article=55465450&symbol=AMBS
ih.advfn.com/...pid=nmona&article=55465450&symbol=AMBS
Artikel / Bericht ist vom 10.12.12. Stelle diesen einfach mal hier rein auf die Gefahr, daß dieser hier schon mal gepostet wurde. Grüße an alle investierten und ein schönes WE.
Grüße aus dem Remstal ;)
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.
Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.
Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:
1.Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2.Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3.Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4.Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Gerald E. Commissiong
President & Chief Executive
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
Grüße aus dem Remstal ;)
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.
Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.
Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:
1.Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2.Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3.Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4.Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Gerald E. Commissiong
President & Chief Executive
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
heute gehts weiter up
squeeze trigger report ist raus:
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Approximately 300 Million Shares Shorted Since June 2011 Short Squeeze Has Begun As Stock Above $0.0379 SqueezeTrigger Price
BUYINS.NET,www.buyins.net,a leading provider of Regulation SHO compliance monitoring,short sale trading statistics and market integrity surveillance,has updated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through December 14,2012. The total aggregate number of shares shorted since June 2011 is approximately 300 million shares. Approximately 28.44% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.0379. A short squeeze has just begun as stock is above its SqueezeTrigger Price.
Click for original Report: www.buyins.com/reports/ambs11-2-12.pdf
squeeze trigger report ist raus:
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Approximately 300 Million Shares Shorted Since June 2011 Short Squeeze Has Begun As Stock Above $0.0379 SqueezeTrigger Price
BUYINS.NET,www.buyins.net,a leading provider of Regulation SHO compliance monitoring,short sale trading statistics and market integrity surveillance,has updated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through December 14,2012. The total aggregate number of shares shorted since June 2011 is approximately 300 million shares. Approximately 28.44% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.0379. A short squeeze has just begun as stock is above its SqueezeTrigger Price.
Click for original Report: www.buyins.com/reports/ambs11-2-12.pdf
Sprechen Sie über die Plattform Drug, MANF!
Mögliche Korrekturen / Kuren für alle folgenden Schritte aus:
MANF für Erkrankungen Über GeneDecksing
OMIM Gen-Informationen: 601916 OMIM Erkrankungen: -
28 Krankheiten MANF:
rheumatoide Arthritis Parkinson Arthritis Karzinom
Lippenspalte Plattenepithelkarzinomen des Kopfes und Halses Cytomegalie-Infektion Hirnverletzung
Wachstumshormonmangel neurodegenerative Erkrankung Neuronitis DNA-Topoisomerase I
Plattenepithelkarzinom glaucomae Glaukom Nierenzellkarzinom Diabetes Alztimers
Twinning Parodontitis Speiseröhrenkrebs Eierstockkrebs
Bauchspeicheldrüsenkrebs Pankreatitis Prostatakrebs Ösophagitis
Retinitis Immundefizienz Hepatitis Prostatitis
Yup, würde ich sagen, wir haben eine BLOCK BUSTER in unseren Händen!
Mögliche Korrekturen / Kuren für alle folgenden Schritte aus:
MANF für Erkrankungen Über GeneDecksing
OMIM Gen-Informationen: 601916 OMIM Erkrankungen: -
28 Krankheiten MANF:
rheumatoide Arthritis Parkinson Arthritis Karzinom
Lippenspalte Plattenepithelkarzinomen des Kopfes und Halses Cytomegalie-Infektion Hirnverletzung
Wachstumshormonmangel neurodegenerative Erkrankung Neuronitis DNA-Topoisomerase I
Plattenepithelkarzinom glaucomae Glaukom Nierenzellkarzinom Diabetes Alztimers
Twinning Parodontitis Speiseröhrenkrebs Eierstockkrebs
Bauchspeicheldrüsenkrebs Pankreatitis Prostatakrebs Ösophagitis
Retinitis Immundefizienz Hepatitis Prostatitis
Yup, würde ich sagen, wir haben eine BLOCK BUSTER in unseren Händen!
Vielen Dank. So knapp 19 Millionen Aktien waren nicht zu liefern, wenn die Cusip Veränderung stattgefunden hat und neue Aktien geliefert werden gibt es eine enorme Menge, die abgedeckt werden muss, an der Spitze der regelmäßigen Shorts. Sehr bullish meiner Meinung nach. Mehr als das Volumen des gestrigen Aktivität, die schöne Gewinne gebracht. Sollte drängen uns letzten Widerstand. Wenn wir gute Daten aus vergleichenden Studie zu bald, dann wird dies schwer laufen (auch, härter als nur die Short-Squeeze). Viel Glück an alle in den Morgen!
Korrektur bis jetzt aus.
Vielleicht schließen wir ja noch im Plus heute.
Lassen wir uns überraschen :-))
Vielleicht schließen wir ja noch im Plus heute.
Lassen wir uns überraschen :-))
Epic Run Coming To Amarantus BioSciences (AMBS)_Institutional And Insider Accumulation_Big News Imminent Predicts Sierra World Equity Review
hab auch schon 350k geladen ;) und kaufe weiter zu! leider wurden 250k in meinem depot noch nicht auf die neu wkn umgeschrieben ;(
mein gefühl sagt mir das wir hier die 0,04 Dollar cent noch mal sehen, kann meine leider so oder so mommentan nicht handeln.Mache mir aber deswegen keine sorgen wir sitzen auf einer bombe.Wenn es so kommt lange ich in berlin wieder zu
Real-Time Best Bid & Ask
0.056 / 0.0585 (1 x 1)Why is size 1?Warum in berlin 0,07 zahlen
0.056 / 0.0585 (1 x 1)Why is size 1?Warum in berlin 0,07 zahlen
Mit der 0,04 wird nichts mehr jetzt kommt 0,25 dann der dollar .Und ich bin pleite keine kohle zum nachkaufen mist!!
Satz nach oben.
Gestern wurde ja einen halben Tag gehandelt.
Ein Plus von knapp 20% mit ca. 15 Mio gehandelten Aktien.
Die Shorties müssen sich vor dem 8.1.13 eindecken :-))
Allen schöne Feiertage.
Gestern wurde ja einen halben Tag gehandelt.
Ein Plus von knapp 20% mit ca. 15 Mio gehandelten Aktien.
Die Shorties müssen sich vor dem 8.1.13 eindecken :-))
Allen schöne Feiertage.
Nichts verkaufen Goldgrube!!!!
zum glück sind meine noch gesperrt sonst hätte ich bestimmt meine ersten 100 % mitgenommen .
zum glück sind meine noch gesperrt sonst hätte ich bestimmt meine ersten 100 % mitgenommen .
Gerald erhalten 125.000.000 Aktien, wenn die Klasse "B" preferred stock wandelt? Bei 0,10 pro Aktie, die 12.500.000 $ ist.
Das ist meine größte sorge wir können nicht handeln und der knallt sie auf den markt !!!
Bis unsere wieder handelbar sind stehen wir wieder bei meinem ek preis.Er kennt die ergebnisse wir leider nicht hoffe aber es wird so nicht kommen.
Das ist meine größte sorge wir können nicht handeln und der knallt sie auf den markt !!!
Bis unsere wieder handelbar sind stehen wir wieder bei meinem ek preis.Er kennt die ergebnisse wir leider nicht hoffe aber es wird so nicht kommen.
Am 26. November 2012, ausgestellt Amarantus BioSciences, Inc. einen Antrag auf sofortige Einstellung des Handels und Dekotierung der Amarantus Stammaktien aus dem Berlin-Bremen Stock Exchange (die "BBSE"), oder sonst irgendwelche inoffiziell regulierten Märkten durch die BBSE gesteuert. Amarantus Stammaktien wurde auf der Berliner Börse ohne Vorkenntnisse, Zustimmung oder Genehmigung aufgeführt. Das Unternehmen hat nicht zulassen oder richten Sie BBSE Broker als Market Maker für die Stammaktien des Unternehmens zu handeln, und glaubt, es war Teil einer organisierten Bemühungen um Restriktionen gegen Leerverkäufe umgehen.
Die unerlaubte Notierung und den Handel auf dem BBSE mag erklären, warum der Aktienkurs der Gesellschaft nicht positiv auf die jüngsten positiven Bekanntmachungen der Gesellschaft umgesetzt werden. Es wird erwartet, Delisting von der BBSE den Aktienhandel in einem üblichen, geregelten Weise zu erleichtern.
Artikel 8,02 Sonstige Veranstaltungen
Am 8. November 2012, ausgestellt Amarantus BioScience, Inc. in einer Pressemitteilung darauf hinweist, dass Daten, die aus der Forschung Zuschuss von der Michael J. Fox Stiftung für die Öffentlichkeit wäre im Dezember 2012 veröffentlicht werden. Das Unternehmen hat beschlossen, die Veröffentlichung der Daten bis zum 8. Januar 2013 um 1:40 Uhr Pazifischer Zeit, als das Unternehmen als Chief Scientific Officer Dr. John W. Commissiong werden die Daten an der OneMedForum 2013 Sir Francis Drake Hotel präsentieren zurückzuhalten San Francisco, CA. Die Präsentation wird im Internet unter onemedplace.com/forum/webcast/ gemacht werden. Die Ursache für die Verzögerung ist das Unternehmen mit führenden Wissenschaftlern und Mitarbeitern verleiht, um verschiedene Aspekte der Daten Ergebnisse zu bestätigen, um eine vollständige Genauigkeit und Transparenz zu gewährleisten. Das Unternehmen glaubt, Bestätigung der Ergebnisse mit den Führern im Bereich vor der Öffentlichkeit zugänglich ist, im besten Interesse ihrer Aktionäre.
Artikel 9,01 Financial Statements and Exhibits
(D) aufweist.
Beweisstück Nr.
4,1 Formular of Rights Agreement, Form des Certificate of Bezeichnungen, Form des Rechts-Zertifikat und die Form der Zusammenfassung der Rechte auf Vorzugsaktien dazu als Exhibit A, B und C angebracht sind Kauf.
99,1 Pressemitteilung kündigt das Timing der Daten durch die Einbeziehung der Unternehmen in Bezug auf seine Zuschuss von der Michael J. Fox Foundation freigegeben werden.
99,2 Pressemitteilung kündigt einen Antrag auf sofortige Einstellung des Handels und Dekotierung der Amarantus Stammaktien aus dem Berlin-Bremen Stock Exchange (die "BBSE"), oder sonst irgendwelche inoffiziell regulierten Märkten durch die BBSE gesteuert. *
Bekommen wir unsere neuen überhaupt noch?
Können die die komplett löschen und wir gehen leer aus?
Die unerlaubte Notierung und den Handel auf dem BBSE mag erklären, warum der Aktienkurs der Gesellschaft nicht positiv auf die jüngsten positiven Bekanntmachungen der Gesellschaft umgesetzt werden. Es wird erwartet, Delisting von der BBSE den Aktienhandel in einem üblichen, geregelten Weise zu erleichtern.
Artikel 8,02 Sonstige Veranstaltungen
Am 8. November 2012, ausgestellt Amarantus BioScience, Inc. in einer Pressemitteilung darauf hinweist, dass Daten, die aus der Forschung Zuschuss von der Michael J. Fox Stiftung für die Öffentlichkeit wäre im Dezember 2012 veröffentlicht werden. Das Unternehmen hat beschlossen, die Veröffentlichung der Daten bis zum 8. Januar 2013 um 1:40 Uhr Pazifischer Zeit, als das Unternehmen als Chief Scientific Officer Dr. John W. Commissiong werden die Daten an der OneMedForum 2013 Sir Francis Drake Hotel präsentieren zurückzuhalten San Francisco, CA. Die Präsentation wird im Internet unter onemedplace.com/forum/webcast/ gemacht werden. Die Ursache für die Verzögerung ist das Unternehmen mit führenden Wissenschaftlern und Mitarbeitern verleiht, um verschiedene Aspekte der Daten Ergebnisse zu bestätigen, um eine vollständige Genauigkeit und Transparenz zu gewährleisten. Das Unternehmen glaubt, Bestätigung der Ergebnisse mit den Führern im Bereich vor der Öffentlichkeit zugänglich ist, im besten Interesse ihrer Aktionäre.
Artikel 9,01 Financial Statements and Exhibits
(D) aufweist.
Beweisstück Nr.
4,1 Formular of Rights Agreement, Form des Certificate of Bezeichnungen, Form des Rechts-Zertifikat und die Form der Zusammenfassung der Rechte auf Vorzugsaktien dazu als Exhibit A, B und C angebracht sind Kauf.
99,1 Pressemitteilung kündigt das Timing der Daten durch die Einbeziehung der Unternehmen in Bezug auf seine Zuschuss von der Michael J. Fox Foundation freigegeben werden.
99,2 Pressemitteilung kündigt einen Antrag auf sofortige Einstellung des Handels und Dekotierung der Amarantus Stammaktien aus dem Berlin-Bremen Stock Exchange (die "BBSE"), oder sonst irgendwelche inoffiziell regulierten Märkten durch die BBSE gesteuert. *
Bekommen wir unsere neuen überhaupt noch?
Können die die komplett löschen und wir gehen leer aus?
chart.consors.is-teledata.com/...PE_IND5=VOLUME&ID_TYPE_S
|
Neueste Beiträge aus dem Amarantus BioScience Inc. Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 1.672 | Amarantus Bioscence - WKN: A1J9ZB - MEGA NEWS $$$$ | Antont | Dr.Schuh | 25.04.21 03:33 | |
| 8 | Ein Milliarden Dollar Unternehmen wurde geboren? | sauerland1502 | krauty77 | 11.01.13 09:00 | ||
| 3 | 137 | Ein Milliarden Dollar Unternehmen wurde geboren? | sauerland1502 | wamu2009 | 02.01.13 16:28 | |
| 30 | Amarantus BioSciences in aller Munde | Balu4u | madeinhell | 18.12.12 08:29 |
